AstraZeneca Offers Update on Immuno-Oncology Program

AstraZeneca plc AZN provided an update on its late-stage immuno-oncology program for first-line non-small cell lung cancer (NSCLC), including amendments of the MYSTIC study, expansion of the NEPTUNE study and initiation of the new PEARL study.

Shares of AstraZeneca have underperformed the Zacks classified Large Cap Pharmaceuticals industry in the past one year, with the stock losing 3.5% while the industry witnessed an increase of 4.3%.

Read Full Article Here >>